MELITAC 12.1 Peptide Vaccine(University of Virginia)(MELITAC 12.1 Peptide Vaccine(University of Virginia))

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

黑色素瘤皮肤黑色素瘤

原研机构

University of Virginia

在研机构-

非在研机构

Oncovir, Inc.

University of Virginia

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 8002

靶点: *****

Sequence Code 10439

Sequence Code 11442

Sequence Code 14810

Sequence Code 51341

Sequence Code 66966

靶点: *****

Sequence Code 67028

靶点: *****

Sequence Code 74015

Sequence Code 74097

Sequence Code 74128

Sequence Code 101057

靶点: *****

Sequence Code 9162241

靶点: *****

Sequence Code 1120173651

靶点: *****

关联

4

项与 MELITAC 12.1 Peptide Vaccine(University of Virginia) 相关的临床试验

NCT01585350 / Completed临床1期IIT

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients, With Evaluation of the Injection Site Microenvironment

The purpose of this study is to learn the effects an experimental vaccine (MELITAC 12.1) combined with other substances called lipopolysaccharide (LPS; endotoxin), polyICLC, and Montanide ISA-51. The LPS, polyICLC, and Montanide ISA-51 are included with the vaccine to test whether they have an effect on the MELITAC 12.1 vaccine. The study will also look at whether the experimental vaccine and these drugs cause any changes to the immune system.

开始日期2012-10-01

申办/合作机构

University of Virginia

[+3]

NCT01264731 / Completed临床1期IIT

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

The purpose of the study is to determine 1) the safety of administration of topical 5% imiquimod cream with or without administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma and 2) evaluate whether topical imiquimod at sites of melanoma metastasis, with or without vaccine, increases a) endothelial expression of E-selectin and b) T cell infiltration.

开始日期2011-01-01

申办/合作机构

University of Virginia

NCT00977145 / Terminated临床1期IIT

Evaluation of the Safety and Immunogenicity of Intratumoral Injection of Interferon Gamma During Vaccination in Patients With Subcutaneous or Cutaneous Metastases of Melanoma

The goals of this study are to evaluate 1) the safety of administration of intratumoral interferon gamma with a peptide-based vaccine, in patients with melanoma and 2) the biological effects of the vaccine. These include an examination of changes within the tumor following vaccination and the evaluation of T cell responses to the vaccine both in the blood and at the sight of tumor.

开始日期2009-11-01

申办/合作机构

University of Virginia

100 项与 MELITAC 12.1 Peptide Vaccine(University of Virginia) 相关的临床结果

登录后查看更多信息

100 项与 MELITAC 12.1 Peptide Vaccine(University of Virginia) 相关的转化医学

登录后查看更多信息

100 项与 MELITAC 12.1 Peptide Vaccine(University of Virginia) 相关的专利（医药）

登录后查看更多信息

100 项与 MELITAC 12.1 Peptide Vaccine(University of Virginia) 相关的药物交易

登录后查看更多信息